Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Trillium Therapeutics Inc. (TRIL) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/29/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
11/22/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/22/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/19/2021 4 Walker Paul Edward (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 5,736,363 shares @ $0
Disposed/sold 850,000 options to buy @ $0.96, valued at $816k
Disposed/sold 6,750,000 options to buy @ $0
Disposed/sold 5,400,000 options to buy @ $0.96, valued at $5.2M
Disposed/sold 40,000 options to buy @ $12.03, valued at $481.2k
11/19/2021 4 Pucci Paolo (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 67,000 options to buy @ $15.5, valued at $1M
11/19/2021 4 Myers Scott Dunseth (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 67,000 options to buy @ $9.51, valued at $637.2k
11/19/2021 4 Harrison Rosemary (See Remarks) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 75 shares @ $0
Disposed/sold 180,000 options to buy @ $14.11, valued at $2.5M
11/19/2021 4 BESHAR LUKE M (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 40,000 options to buy @ $12.03, valued at $481.2k
Disposed/sold 6,666 options to buy @ $0
Disposed/sold 547,656 restricted stock units @ $0
11/19/2021 4 Parsons James T. (CFO) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 180,000 options to buy @ $12.03, valued at $2.2M
Disposed/sold 94,792 options to buy @ $0
Disposed/sold 59,896 options to buy @ $0
Disposed/sold 5,761 options to buy @ $0
Disposed/sold 36,204 options to buy @ $0
Disposed/sold 24,390 options to buy @ $0
Disposed/sold 30,171 options to buy @ $0
11/19/2021 4 Kamarck Michael E. (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 67,000 options to buy @ $14.77, valued at $989.6k
11/19/2021 4 Looker Benjamin (General Counsel) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 190,000 options to buy @ $9.51, valued at $1.8M
11/19/2021 4 MACKEY CATHERINE J (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 67,000 options to buy @ $9.7, valued at $649.9k
11/19/2021 4 Bruns Ingmar (Chief Medical Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 400,000 options to buy @ $14.11, valued at $5.6M
11/19/2021 4 Petrova Penka (Chief Development Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 38,808 options to buy @ $0
Disposed/sold 4,574 options to buy @ $0
Disposed/sold 49,480 options to buy @ $0
Disposed/sold 83,960 options to buy @ $0
Disposed/sold 140,000 options to buy @ $12.03, valued at $1.7M
11/19/2021 4 Uger Robert (Chief Scientific Officer) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 102,083 options to buy @ $0
Disposed/sold 58,333 options to buy @ $0
Disposed/sold 5,260 options to buy @ $0
Disposed/sold 23,473 options to buy @ $0
Disposed/sold 29,073 options to buy @ $0
Disposed/sold 250,000 options to buy @ $12.03, valued at $3M
11/19/2021 4 TAYTON-MARTIN HELEN KATRINA (Director) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 40,000 options to buy @ $12.03, valued at $481.2k
Disposed/sold 498,294 restricted stock units @ $0
11/19/2021 4 Skvarka Jan (President and CEO) has filed a Form 4 on Trillium Therapeutics Inc.
Txns: Disposed/sold 197,000 options to buy @ $0
Disposed/sold 1,162,500 options to buy @ $0
Disposed/sold 600,000 options to buy @ $12.03, valued at $7.2M
11/19/2021 SC 13D/A Growth Equity Opportunities V, LLC has filed a Schedule 13D for Trillium Therapeutics Inc.
11/17/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/17/2021 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
11/17/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/17/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
11/17/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
11/17/2021 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Pfizer Completes Acquisition of Trillium Therapeutics"
11/17/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
11/16/2021 8-K Other Events  Interactive Data
11/12/2021 10-Q Quarterly Report for the period ended September 30, 2021
10/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Trillium Therapeutics Receives Final Court Order Approving Arrangement"
10/27/2021 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &...
Docs: "Trillium Securityholders Approve Acquisition by Pfizer CAMBRIDGE, MA, October 26, 2021 / GlobeNewsWire / Trillium Therapeutics Inc. today announced that its securityholders approved a statutory arrangement with PF Argentum ULC a wholly-owned, indirect subsidiary of Pfizer Inc. at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates. The special resolution approving the arrangement was approved by: 99.61% of the votes cast by Trillium shareholders voting as a single class present in person or represented by proxy and entitled to vote at the meeting; and 99.64% of the votes cast by Trillium shareholders ..."
10/20/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/20/2021 8-K Other Events  Interactive Data
10/15/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/15/2021 8-K Other Events  Interactive Data
10/13/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy